Immatics NV
NASDAQ:IMTX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.58
13.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Immatics NV
Immatics NV
Accounts Receivables
Immatics NV
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immatics NV
NASDAQ:IMTX
|
Accounts Receivables
€4.1m
|
CAGR 3-Years
47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Accounts Receivables
€2.2B
|
CAGR 3-Years
136%
|
CAGR 5-Years
158%
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Accounts Receivables
€25.9m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
CureVac NV
NASDAQ:CVAC
|
Accounts Receivables
€17.1m
|
CAGR 3-Years
112%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Accounts Receivables
€170m
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
0%
|
|
|
Formycon AG
XETRA:FYB
|
Accounts Receivables
€28.2m
|
CAGR 3-Years
54%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
Immatics NV
Glance View
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 188 full-time employees. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
See Also
What is Immatics NV's Accounts Receivables?
Accounts Receivables
4.1m
EUR
Based on the financial report for Dec 31, 2023, Immatics NV's Accounts Receivables amounts to 4.1m EUR.
What is Immatics NV's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
47%
Over the last year, the Accounts Receivables growth was 272%. The average annual Accounts Receivables growth rates for Immatics NV have been 47% over the past three years .
You don't have any saved screeners yet
